Continuing its goal in bridging the gap in patient recruitment, 1nHealth partners with Curavit Clinical Research, a virtual contract research organization that designs and executes Decentralized Clinical Trials (DCT). The announced collaboration accelerates patient enrollment in clinical trials and is expected to boost program retention. 1nHealth and Curavit’s initial teaming up is for Lark Health’s investigational digital therapeutic for chronic cardiovascular disease.
The Lark Heart Health Program
Earlier this year, Lark and Roche Diagnostics announced the creation of their cutting-edge AI-driven initiative for the prevention and control of atherosclerotic cardiovascular disease (ASCVD) and coronary artery disease (CAD). The Lark Heart Health program offers individualized health coaching whenever and wherever you need it. It is an AI-driven virtual care solution.
The objective of Lark’s Heart Health program is to coordinate care in managing risk factors for cardiovascular disease (CVD) and to lower the prevalence of recurring heart conditions or incidents. In order to attract and motivate patients, the smartphone-based program addresses CVD risk factors like food, exercise, and tobacco use. It does this by utilizing conversational AI, connected devices, and remote patient monitoring.
CBT Framework, Basis for Lark’s AI Cardio Initiative
Lark Heart Health, which was developed using a Cognitive Behavioral Therapy (CBT) framework and in accordance with American Heart Association (AHA) recommendations, will offer a scalable, affordable option for ongoing, person-centered remote heart health coaching. This coaching is meant to assist users in improving their healthy lifestyle behaviors, lowering stress levels, and ultimately lowering risk factors for heart disease. Lark will give users the tools they need to make significant lifestyle changes that will help them better prevent and treat ASCVD and CAD through an evidence-based educational program and real-time individualized coaching.
Collaborative Patient Engagement Speeds Up Enrollment
In excess of the expectations of the sponsor, 1nHealth successfully recruited qualifying patients for Lark’s Heart Health trial through paid advertising on important digital media platforms (such as Facebook, Instagram, Google, and Reddit). Moreover, almost 40% of patients who clicked on an advertisement continued to fill out the pre-screen form. Well beyond initial successful 10-day recruitment drive, Curavit and 1nHealth have promptly and effectively attracted, obtained consent from, and enrolled a total of 150 patients.
In order to track progress and ensure the greatest impact on each participant, the collaborative team’s capacity to engage with the right patient at the right time was crucial during the program’s early phase. This is according to Dr. OraLee Branch, director of clinical studies at Lark Health. Lark Health was able to accomplish its objective because of Curavit and 1nHealth’s creative patient engagement strategies. Additionally, the quick patient enrollment helps Lark Health achieve its goal of aiding patients who are prone to a life-threatening sickness or condition.
A further unaccounted-for cost of the COVID-19 pandemic in terms of lives and quality of life was caused by delays in getting potentially helpful medications to patients in need. The COVID-19 pandemic delayed many clinical trials that were possibly bringing new treatments to market. But for the foreseeable future, the industry will be propelled by DCTs’ unquestionable success to make them the standard. Vanguards of the industry, like 1nHealth, deliver the novel tools and ways of thinking that will hasten the adoption of new therapies by more people. The Lark Heart Health program will be commercially available in the first quarter of 2023.
Engr. Dex Marco Tiu Guibelondo, BS Pharm, RPh, BS CpE
Editor-in-Chief, PharmaFEATURES
Web Media Acknowledgements
(1) Clinical Trials image used in this article is adapted from a News Medical article entitled The Advantages of Decentralized Clinical Trials. The article was authored by Naveen Dha. Article was published on 13 May, 2022. Image copyright all goes to Den Rise from Shuttershock. The image was retrieved on November 10, 2022 from https://www.news-medical.net/life-sciences/What-is-a-Decentralized-Clinical-trial.aspx.
(2) Slightly modified AI in Cardiology image used in this article is adapted from an Analytics Steps Artificial Intelligence article entitled 4 Uses of AI In Cardiology. Institutional Report was published on 22 June, 2021. The article is authored by Manisha Sahu. The image was retrieved on November 10, 2022 from https://www.analyticssteps.com/blogs/4-uses-ai-cardiology.
(3) Value addition of artificial intelligence in almost every phase of cardiac imaging image used in this article is adapted from a Keya Medical article entitled Cardiovascular Imaging AI Applications. Article was published on 02 Sept 2020. The image was retrieved on November 10, 2022 from https://www.keyamedical.com/esc-cardiovascular-imaging-ai/.
(4) CBT image used in this article is adapted from an Alabama Psychological Services Center LLC article entitled Behavior Therapy. Website was last updated on 2021. The image was retrieved on November 10, 2022 from https://www.alapsych.com/behavior-therapy/.
(5) The collaborative right patient engagement image used in this article is adapted from an HealthPartner Institute article entitled Clinical trials at HealthPartners Institute. Website was last updated on 2022 The image was retrieved on November 10, 2022 from https://www.healthpartners.com/institute/research/participate-research-study/learn-clinical-trials/.